ISO 10993-6 Update: Implantation Test Methods for Medical Devices

ISO 10993-6 is part of the ISO 10993 series, a globally recognized framework for the biological evaluation of medical devices. Specifically, Part 6 focuses on implantation studies, which are designed to assess the local effects of medical devices or materials when placed within living tissue. These studies play a critical role in determining biocompatibility by evaluating how surrounding tissues respond over time, supporting safety assessments required for regulatory approval.

Historically, implantation testing under ISO 10993-6 has included a range of well-established in vivo methods, such as subcutaneous, intramuscular, and bone implantation models. These studies have been used to evaluate key biological endpoints including acute and chronic inflammation, fibrous capsule formation, necrosis, neovascularization, and material degradation or resorption. Semi-quantitative histopathological scoring systems and comparative assessments against control materials have long been central to interpreting these responses.

Data generated from these earlier implantation tests have had a significant impact on the evolution of medical device design and risk management practices. For example, adverse findings related to persistent inflammation or poor tissue integration have led to the refinement of biomaterial compositions, improvements in surface engineering, and the development of more biocompatible coatings. Similarly, insights into degradation profiles have informed the safe use of absorbable materials in applications such as sutures, orthopedic fixation devices, and drug delivery systems.

Regulatory expectations have also been shaped by historical implantation data, reinforcing the importance of robust study design, appropriate control selection, and timepoint evaluation to capture both early and long-term tissue responses. These lessons have contributed to safer, more effective devices and have supported a more predictive approach to preclinical evaluation.

The latest revision of ISO 10993-6 builds on this foundation by incorporating current scientific understanding, modernized terminology, and expanded guidance to address increasingly complex medical technologies, including combination products and tissue-engineered medical products. It also outlines updated requirements for implantation test methods used in the preclinical assessment of local tissue effects following the implantation of medical devices and materials, particularly for devices that breach skin or mucosal surfaces and require evaluation of localized biological responses.

The document covers a broad range of materials, including solid and non-solid forms such as porous structures, liquids, gels, pastes, powders, and particulates. It also applies to absorbable, degradable, non-absorbable materials, as well as tissue-engineered medical products (TEMPs).

Importantly, the standard focuses on assessing local tissue responses—such as inflammation, integration, degradation, and absorption—within appropriate animal models. It is not intended to evaluate mechanical performance or functional characteristics of devices, nor does it provide guidance on systemic toxicity, carcinogenicity, mutagenicity, or reproductive toxicity. However, study designs may be adapted to capture additional biological endpoints where appropriate.

Key Updates in the Latest Edition

This revised edition introduces several important enhancements:

• New definitions, including terms such as “comparative control,” “coupon,” “local effect,” “reference control,” and “steady-state”
• Expanded guidance on the use of representative sample “coupons” for complex devices
• A new section on the selection of control materials
• Additional considerations for evaluating lymph node responses
• New annexes covering:
  • Test methods for devices contacting peripheral nerve tissue
  • Microscopic evaluation of tissue responses
• Updated tissue and pathological terminology
• Revised and expanded bibliography

Study Design Considerations

The standard emphasizes the importance of thoughtful study design, including:

• Selection of appropriate anatomical implantation sites
• Use of comparative or reference control materials with established clinical performance
• Opportunities to integrate multiple biological endpoints into a single study to reduce animal use

In some cases, long-term systemic toxicity studies may be designed to incorporate implantation endpoints, aligning with broader biological evaluation requirements.

Scope and Application

ISO 10993-6 remains a critical component of the biological evaluation framework for medical devices, supporting the assessment of local tissue compatibility as part of a risk-based approach to safety. It should be used in conjunction with other standards in the ISO 10993 series, particularly those addressing general biological evaluation principles, animal welfare, degradation products, and sample preparation.

For organizations developing or evaluating medical devices, this update reinforces the need for rigorous, well-designed implantation studies to support regulatory submissions and ensure patient safety.

Conclusion

The updated ISO 10993-6 standard provides clearer definitions, expanded guidance, and improved alignment with current scientific and regulatory expectations for implantation testing. These updates help manufacturers design more robust, efficient studies while ensuring comprehensive evaluation of local tissue responses. Adhering to these requirements is essential for demonstrating biocompatibility and supporting successful regulatory submissions.

For support with your regulatory strategy, implantation study design, or biological evaluation requirements, please reach out to us at info@mdiconsultants.com or use our contact form on our website https://mdiconsultants.com/contact/